Biosimilars: Complements and Comments on the Recent Statement of the SFR and CRI. Comment On: “biosimilars: an Opportunity. Position Statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).” Schaeverbeke Et Al. Joint Bone Spine 2018;95:399-402